共查询到20条相似文献,搜索用时 828 毫秒
1.
乳铁蛋白在过去的年中被广泛研究 其多种生物学作用被科学界普遍接受。它不仅参与铁的储存和转运 而且具有抗微生物抗氧化抗肿瘤调节免疫系统功能等作用 被认为是一种新型的抗菌抗癌物质。乳铁蛋白及其衍生物的外源性治疗可有效抑制肿瘤的生长并降低肿瘤发生的敏感性。乳铁蛋白主要通过细胞膜破坏凋亡诱导细胞周期阻滞和细胞免疫反应等途径发挥抗肿瘤作用。然而 关于乳铁蛋白抗肿瘤作用的潜在机制 目前还未完全明确。本文综述了乳铁蛋白及其衍生物抗肿瘤的作用及机制研究。在这些机制的基础上 提出了应用乳铁蛋白和/或其衍生物抗肿瘤作用的新策略 讨论了乳铁蛋白及其衍生物在抗肿瘤研究领域的潜力。 《肿瘤代谢与营养电子杂志》2021,8(1):105-109
乳铁蛋白在过去的70年中被广泛研究,其多种生物学作用被科学界普遍接受。它不仅参与铁的储存和转运,而
且具有抗微生物、抗氧化、抗肿瘤、调节免疫系统功能等作用,被认为是一种新型的抗菌、抗癌物质。乳铁蛋白及其衍生物的外
源性治疗可有效抑制肿瘤的生长并降低肿瘤发生的敏感性。乳铁蛋白主要通过细胞膜破坏、凋亡诱导、细胞周期阻滞和细胞
免疫反应等途径发挥抗肿瘤作用。然而,关于乳铁蛋白抗肿瘤作用的潜在机制,目前还未完全明确。本文综述了乳铁蛋白及
其衍生物抗肿瘤的作用及机制研究。在这些机制的基础上,提出了应用乳铁蛋白和/或其衍生物抗肿瘤作用的新策略,讨论了
乳铁蛋白及其衍生物在抗肿瘤研究领域的潜力。 相似文献
2.
T138067是一类在磺胺结构基础上合成的新化合物,由于其独特的以微管为作用靶点,已成为抗肿瘤治疗研究的热点之一。现综述其抗肿瘤作用机制、应用研究、抗耐药性等方面的研究进展。 相似文献
3.
4.
超抗原SEA抗肿瘤作用研究进展 总被引:2,自引:0,他引:2
许从峰 《国外医学(肿瘤学分册)》2001,28(3):165-166
SEA由于其强大的抗肿瘤作用受到人们的日益重视,本文综述其抗肿瘤作用的机制以及实验研究的最新进展。 相似文献
5.
6.
7.
近年来,随着天然药物化学分离和提纯技术水平的不断提高,以及药理学研究的深入,当归抗肿瘤活性成分作用机制的研究取得了较大进展。对当归有效成分进行研究后,发现其具有抗肿瘤、调节免疫、造血、抗血小板聚集、平喘和镇痛等多种作用。当归抗肿瘤作用机制主要包括抑制肿瘤血管生成、影响肿瘤细胞周期、抑制肿瘤细胞生长和增殖、诱导肿瘤细胞凋亡、降低黏附性和侵袭力、抑制肿瘤细胞转移、逆转肿瘤耐药和放化疗增敏等。本文通过对国内外相关文献进行系统梳理和归纳,为明确当归抗肿瘤作用机制和新型抗肿瘤药物的研发提供参考。 相似文献
8.
白细胞介素21(IL-21)作为新的免疫系统调节因子, 在免疫调节、抗肿瘤中的作用已经成为近年来的研究热点。白细胞介素21受体(IL-2lR)表达在大多数的淋巴细胞, 对多种免疫细胞, 包括B淋巴细胞、T淋巴细胞、NK细胞和树突状细胞都有重要的生物调节作用, 进而在宿主抗肿瘤免疫和许多癌症的免疫治疗中具有一定作用。许多研究已经证实IL-21对于多种恶性肿瘤发挥良好的抗肿瘤作用, 并且部分已应用于临床。新近的研究表明, IL-21对于不同的血液肿瘤具有不同的作用, 如对B细胞慢性淋巴细胞白血病、非霍奇金淋巴瘤和白血病, 其可以发挥抗肿瘤作用, 此作用机制包括直接抗肿瘤作用及通过作用于免疫细胞发挥间接的抗肿瘤作用。而对于霍奇金淋巴瘤和多发性骨髓瘤则表现为促进肿瘤细胞的生长, 其作用机制包括通过激活相应的信号途径和作用于相应的细胞因子。本文对IL-21的免疫调节功能及其在血液肿瘤中的相关研究进行综述。 相似文献
9.
10.
11.
Berlin JD Venook A Bergsland E Rothenberg M Lockhart AC Rosen L 《Clinical colorectal cancer》2008,7(1):44-47
BACKGROUND: This study was conducted before the approval of oxaliplatin, cetuximab, and bevacizumab and was designed to evaluate a novel microtubule targeting agent, T138067, in patients with metastatic colorectal cancer (CRC) previously treated with irinotecan and 5-fluorouracil. PATIENTS AND METHODS: Patients from 3 institutions were enrolled over 4 months and treated with T138067 on days 1, 8, and 15 of a 21-day cycle. Disease evaluation was performed after 9 weeks. RESULTS: Treatment was tolerable with moderate hematologic and gastrointestinal toxicity. Neurotoxicity, an expected side effect, was minimal. Among 23 evaluable patients, there were no responses. Median time to tumor progression was 1.4 months and median survival was 9.3 months. CONCLUSION: T138067 at this dose and schedule was well tolerated by patients with CRC. However, there was no evidence of clinical activity for T138067 in 5-fluorouracil/irinotecan-refractory CRC. The long median survival likely reflects availability of other agents and/or patient selection. 相似文献
12.
Kirby S Gertler SZ Mason W Watling C Forsyth P Aniagolu J Stagg R Wright M Powers J Eisenhauer EA 《Neuro-oncology》2005,7(2):183-188
We studied the activity of T138067-sodium in patients with malignant gliomas. T138067-sodium is a unique new chemotherapy agent that inhibits microtubule formation by binding irreversibly and specifically to beta(1), beta(2)and beta(4) isotypes of 3-tubulin, causing cell arrest at G(2)/M and inducing apoptosis. Patients with recurrent anaplastic astrocytoma or glioblastoma multiforme were treated intravenously with 330 mg/m(2) of T138067-sodium weekly. Treatment was continued until the patient experienced either unacceptable toxicity or progressive disease. Patients had to have histologically proven glioma, have bidimensionally measurable disease at least 1 cm x 1 cm, and have received no more than one prior adjuvant chemotherapy. No chemotherapy or radiotherapy for recurrent disease was permitted. Nineteen patients entered the trial. One patient was found to be ineligible. There were two patients with anaplastic astrocytoma and 16 with glioblastoma multiforme. Only two patients had received prior adjuvant chemotherapy. The first seven patients had full pharmacokinetic sampling. No dose-limiting toxicity was seen, and pharmacokinetic results were consistent with those from nonglioma patients. The most common drug-related effects were fatigue (33%), nausea (28%), neutropenia (28%), and anorexia (17%). No patients stopped the study because of toxicity. No responses were seen in the 15 eligible patients who completed at least one cycle. Three patients had stable disease with a median duration of 2.6 months. Our results suggest that given in this dose and schedule T138067-sodium does not have activity in this population of anaplastic astrocytoma and glioblastoma multiforme. 相似文献
13.
14.
15.
恶性肿瘤是目前严重威胁人类生命健康的重大疾病之一,随着对恶性肿瘤研究的深入,越来越多的抗肿瘤药物被研发应用并取得显著的成效,但是由于复杂的肿瘤微环境,抗肿瘤药物常难以渗透至肿瘤组织深部,导致生物利用度低,抗肿瘤作用减弱。肿瘤穿透肽(tumor-penetrating peptide)iRGD化学连接在纳米载体表面或者与纳米载体联合给药,促进药物渗透至肿瘤组织深部有效发挥抗肿瘤作用,是目前肿瘤靶向治疗领域中备受关注的研究方向之一。本文回顾并总结了iRGD在抗肿瘤靶向纳米递药治疗中的研究进展,这些研究结果都显示了肿瘤穿透肽iRGD在肿瘤靶向治疗中拥有良好的应用前景。 相似文献
16.
17.
Yujia Peng Yiran Tao Ya Zhang Jiaxing Wang Jinliang Yang Yuxi Wang 《International journal of cancer. Journal international du cancer》2023,152(7):1290-1303
CD25 is the alpha-chain of the heterotrimer IL-2 receptor. CD25 is expressed on the surface of both immune and non-immune cells with different frequencies. For cancers, CD25 is expressed at high levels in many types of hematological malignancies, but at low levels in most solid tumors. CD25 is also highly expressed in activated circulating immune cells and regulatory T cells (Tregs). Infiltration of Tregs in the tumor microenvironment can lead to an imbalanced ratio of effector T cells (Teffs) and Tregs, which is associated with the progression of cancers. A rescued Teff/Treg cell ratio indicates an efficient anti-tumor response to immunotherapy. CD25 as a potential target for the depletion of Tregs is critical in developing new immunotherapeutic strategies. Few articles have summarized the relationships between CD25 and tumors, or the recent progress of drugs targeting CD25. In this paper, we will discuss the structures of IL-2 and IL-2R, the biological function of CD25 and its important role in tumor therapy. In addition, the latest research on drugs targeting CD25 has been summarized, providing guidance for future drug development. 相似文献
18.
19.